Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 5
2019 11
2020 13
2021 13
2022 14
2023 8
2024 11
2025 10
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean gepant ubrogepant megepant migraine (133 results)?
Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment.
Pellesi L, Jedie B, Barhum F, Al-Abdullah S, Martelletti P, Xiao Z. Pellesi L, et al. Pain Manag. 2025 May;15(5):279-284. doi: 10.1080/17581869.2025.2494494. Epub 2025 Apr 16. Pain Manag. 2025. PMID: 40238598 Free PMC article. Review.
This review examines the efficacy and safety of gepants - ubrogepant, rimegepant, and zavegepant - in the acute treatment of migraine. We assessed phase II and III clinical trials, focusing on clinically relevant endpoints such as pain freedom and freedom fro …
This review examines the efficacy and safety of gepants - ubrogepant, rimegepant, and zavegepant - in the acute treatment of …
Diagnosis and Management of Headache: A Review.
Robbins MS. Robbins MS. JAMA. 2021 May 11;325(18):1874-1885. doi: 10.1001/jama.2021.1640. JAMA. 2021. PMID: 33974014 Review.
Patients with or at high risk for cardiovascular disease should avoid triptans because of vasoconstrictive properties. Acute treatments with gepants, antagonists to receptors for the inflammatory neuropeptide calcitonin gene-related peptide, suc …
Patients with or at high risk for cardiovascular disease should avoid triptans because of vasoconstrictive properties. Acute treatments with …
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. Ailani J, et al. Headache. 2021 Jul;61(7):1021-1039. doi: 10.1111/head.14153. Epub 2021 Jun 23. Headache. 2021. PMID: 34160823
OBJECTIVE: To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults. BACKGROUND: The American Headache Society previously published a Consensus Stateme …
OBJECTIVE: To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute …
Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis.
Laohapiboolrattana W, Jansem P, Anukoolwittaya P, Roongpiboonsopit D, Hiransuthikul A, Pongpitakmetha T, Thanprasertsuk S, Rattanawong W. Laohapiboolrattana W, et al. J Headache Pain. 2024 Nov 8;25(1):194. doi: 10.1186/s10194-024-01904-1. J Headache Pain. 2024. PMID: 39516789 Free PMC article.
We included randomized controlled trials (RCTs) that compared novel abortive treatments, including lasmiditan, rimegepant, and ubrogepant, in migraine patients who self-reported insufficient response to triptans. ...However, lasmiditan 200 mg had the highest …
We included randomized controlled trials (RCTs) that compared novel abortive treatments, including lasmiditan, rimegepant, and ubr …
Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis.
Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ. Yang CP, et al. JAMA Netw Open. 2021 Oct 1;4(10):e2128544. doi: 10.1001/jamanetworkopen.2021.28544. JAMA Netw Open. 2021. PMID: 34633423 Free PMC article.
IMPORTANCE: New therapeutic classes of migraine-specific treatment have been developed, including 5-hydroxytryptamine1F receptor agonists (lasmiditan) and calcitonin gene-related peptide antagonists (rimegepant and ubroge …
IMPORTANCE: New therapeutic classes of migraine-specific treatment have been developed, including 5-hydroxytryptamine1F receptor …
Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases.
Liang Q, Liao X, Wu H, Huang Y, Liang T, Li H. Liang Q, et al. Front Pharmacol. 2024 Jul 31;15:1431562. doi: 10.3389/fphar.2024.1431562. eCollection 2024. Front Pharmacol. 2024. PMID: 39144633 Free PMC article.
Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. As novel migraine therapies, gepants act by targeting the calcitonin gene-related peptide (CGRP) pathway, demonstrating effective control of migraine atta …
Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. As novel migraine therapies, gepants act by targe …
Cost-effectiveness analysis of ubrogepant, rimegepant, and zavegepant for acute migraine treatment vs usual care.
Gokhale P, Villa Zapata L. Gokhale P, et al. Am J Manag Care. 2025 Nov 1;31(11):e322-e328. doi: 10.37765/ajmc.2025.89822. Am J Manag Care. 2025. PMID: 41289290 Free article.
Small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists, also referred to as gepants , provide third-line treatment options for patients refractory to first- and second-line therapies. ...CONCLUSIONS: Ubrogepant, …
Small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists, also referred to as ge …
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.
Polavieja P, Belger M, Venkata SK, Wilhelm S, Johansson E. Polavieja P, et al. J Headache Pain. 2022 Jul 6;23(1):76. doi: 10.1186/s10194-022-01440-w. J Headache Pain. 2022. PMID: 35790906 Free PMC article.
BACKGROUND: In the absence of head-to-head trials, comprehensive evidence comparing onset of efficacy of novel agents for acute treatment of migraine is lacking. This study aimed to explore the relative efficacy of lasmiditan (serotonin [5-hydroxytryptamine] 1F receptor …
BACKGROUND: In the absence of head-to-head trials, comprehensive evidence comparing onset of efficacy of novel agents for acute treatment of …
Gepants.
Tepper D. Tepper D. Headache. 2020 May;60(5):1037-1039. doi: 10.1111/head.13791. Headache. 2020. PMID: 32337726 No abstract available.
Headache: Treatment update.
Ogunlaja OI, Goadsby PJ. Ogunlaja OI, et al. eNeurologicalSci. 2022 Aug 17;29:100420. doi: 10.1016/j.ensci.2022.100420. eCollection 2022 Dec. eNeurologicalSci. 2022. PMID: 36636337 Free PMC article. Review.
Primary headache disorders in particular migraine are one of the most common causes of disability worldwide. Given the high burden of migraine in terms of disability, there has been an effort to develop migraine specific therapies that has led to the a …
Primary headache disorders in particular migraine are one of the most common causes of disability worldwide. Given the high bu …
88 results